Cargando…

Clinical Trial Simulations From a Model‐Based Meta‐Analysis of Studies in Patients With Advanced Hepatocellular Carcinoma Receiving Antiangiogenic Therapy

A mixed effect model describing median overall survival (mOS) in patients with advanced hepatocellular carcinoma (aHCC) treated with antiangiogenic therapy (AAT) was developed from literature data. Data were extracted from 59 studies, representing 4,813 patients. The final model included estimates o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zierhut, ML, Chen, Y, Pithavala, YK, Nickens, DJ, Valota, O, Amantea, MA
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879476/ https://www.ncbi.nlm.nih.gov/pubmed/27299940 http://dx.doi.org/10.1002/psp4.12078

Ejemplares similares

Combination Antiangiogenic and Immunotherapy for Advanced Hepatocellular Carcinoma: Evidence to Date
por: Raybould, Alison L, et al.
Publicado: (2020)

Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety
por: Welker, Martin-Walter, et al.
Publicado: (2013)

AATF inhibition exerts antiangiogenic effects against human hepatocellular carcinoma
por: Suresh, Diwakar, et al.
Publicado: (2023)

Can we develop effective combination antiangiogenic therapy for patients with hepatocellular carcinoma?
por: Wenger, Justin B., et al.
Publicado: (2011)

Resistance to Antiangiogenic Therapy in Hepatocellular Carcinoma: From Molecular Mechanisms to Clinical Impact
por: Federico, Piera, et al.
Publicado: (2022)

A case for the use of receiver operating characteristic analysis of potential clinical efficacy biomarkers in advanced renal cell carcinoma
por: English, Patricia A, et al.
Publicado: (2016)

Pulmonary cavitation in patients with thyroid cancer receiving antiangiogenic agents
por: Datar, Saumil, et al.
Publicado: (2020)

Efficacy and safety of immune checkpoint inhibitors-combined antiangiogenic drugs in the treatment of hepatocellular carcinoma: A systematic review and meta analysis
por: Zhong, Yu, et al.
Publicado: (2022)

Antiangiogenic therapy for advanced renal cell carcinoma: Management of treatment-related toxicities
por: Cohen, Roger B., et al.
Publicado: (2012)

Antiangiogenic effects of pazopanib in xenograft hepatocellular carcinoma models: evaluation by quantitative contrast-enhanced ultrasonography
por: Zhu, Xiao-Dong, et al.
Publicado: (2011)

Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma
por: Ikeda, Masafumi, et al.
Publicado: (2014)

Combining antiangiogenic therapy and radiation in nasopharyngeal carcinoma
por: Chen, Zhuo, et al.
Publicado: (2015)

Case Report: Antiangiogenic Therapy Plus Immune Checkpoint Inhibitors Combined With Intratumoral Cryoablation for Hepatocellular Carcinoma
por: Li, Xin, et al.
Publicado: (2021)

Risk of antiangiogenic adverse events in metastatic colorectal cancer patients receiving aflibercept in combination with chemotherapy: A meta-analysis
por: Ge, Pu, et al.
Publicado: (2023)

Advances in antiangiogenic treatment of small-cell lung cancer
por: Lu, Hongyang, et al.
Publicado: (2017)

Clinical benefit of antiangiogenic therapy in advanced and metastatic chondrosarcoma
por: Jones, Robin L., et al.
Publicado: (2017)

Recent Advancements of Nanomedicine towards Antiangiogenic Therapy in Cancer
por: Mukherjee, Anubhab, et al.
Publicado: (2020)

Oral Side Effects in Patients with Metastatic Renal Cell Carcinoma Receiving the Antiangiogenic Agent Pazopanib—Report of Three Cases
por: Papadopoulou, Erofili, et al.
Publicado: (2022)

Antiangiogenic therapy
por: Avitabile, T
Publicado: (2010)

Water-Exchange-Modified Kinetic Parameters from Dynamic Contrast-Enhanced MRI as Prognostic Biomarkers of Survival in Advanced Hepatocellular Carcinoma Treated with Antiangiogenic Monotherapy
por: Lee, Sang Ho, et al.
Publicado: (2015)

Antiangiogenic and antihepatocellular carcinoma activities of the Juniperus chinensis extract
por: Kuo, Zong-Keng, et al.
Publicado: (2016)

(18)F-RGD PET/CT and Systemic Inflammatory Biomarkers Predict Outcomes of Patients With Advanced NSCLC Receiving Combined Antiangiogenic Treatment
por: Liu, Jie, et al.
Publicado: (2021)

Immunotherapy and Antiangiogenic Therapy for the Treatment of Patients With Advanced Renal Cell Carcinoma: A Systematic Review and an Updated Network Meta-Analysis of Phase III Clinical Trials
por: Patel, Rushin, et al.
Publicado: (2023)

Advanced lung cancer inflammation index predicts survival outcomes of hepatocellular carcinoma patients receiving immunotherapy
por: Li, Qian, et al.
Publicado: (2023)

Navigating and adapting care integrating immunotherapy, antiangiogenic therapy, and combinations in patients with advanced renal cell carcinoma
por: Rini, Brian I, et al.
Publicado: (2023)

Evaluation of the impact of transient interruption of antiangiogenic treatment using ultrasound-based techniques in a murine model of hepatocellular carcinoma
por: Marinelli, Sara, et al.
Publicado: (2014)

Antiangiogenic and Antitumor Activities of Aflibercept, a Soluble VEGF Receptor-1 and -2, in a Mouse Model of Hepatocellular Carcinoma
por: Torimura, Takuji, et al.
Publicado: (2016)

Efficacy and safety of PD‐1 inhibitor combined with antiangiogenic therapy for unresectable hepatocellular carcinoma: A multicenter retrospective study
por: Yao, Junlin, et al.
Publicado: (2022)

Case of Tracheoesophageal Fistula Formation as a Rare Complication of Antiangiogenic Tyrosine Kinase Inhibitor Therapy for Metastatic Hepatocellular Carcinoma
por: Adeoye, Oluwatayo, et al.
Publicado: (2023)

The inefficacy of antiangiogenic therapies
por: Ribatti, Domenico
Publicado: (2010)

Antiangiogenic Therapy for Glioma
por: Cea, Valentina, et al.
Publicado: (2012)

Antiangiogenic Cancer Therapy
por: Maxwell, P H, et al.
Publicado: (2009)

Antiangiogenic effects of oridonin
por: Tian, Lili, et al.
Publicado: (2017)

Antiangiogenic Effect of Alkaloids
por: Alasvand, Masoud, et al.
Publicado: (2019)

Antiangiogeneic Strategies in Mesothelioma
por: Nowak, Anna K., et al.
Publicado: (2020)

Antiangiogenic Activity of Flavonoids: A Systematic Review and Meta-Analysis
por: Khater, Mai, et al.
Publicado: (2020)

PD-L1 expression on circulating tumor cells can be a predictive biomarker to PD-1 inhibitors combined with radiotherapy and antiangiogenic therapy in advanced hepatocellular carcinoma
por: Su, Ke, et al.
Publicado: (2022)

Lenvatinib for effectively treating antiangiogenic drug-resistant nasopharyngeal carcinoma
por: Sun, Qi, et al.
Publicado: (2022)

Recent Advances and Impact of Chemotherapeutic and Antiangiogenic Nanoformulations for Combination Cancer Therapy
por: Rajora, Amit Kumar, et al.
Publicado: (2020)

Polyethylene glycol–poly(ε-benzyloxycarbonyl-l-lysine)-conjugated VEGF siRNA for antiangiogenic gene therapy in hepatocellular carcinoma
por: Wang, Gangmin, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_4sirfjf8op9jt9urr63f98g8ul